Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.

Abstract

PURPOSE OF REVIEW:

This review aims to summarize the role of the interleukin-1 (IL-1) blocking agents in cardiovascular diseases, briefly describing the pathogenetic rationale and the most relevant clinical studies.

RECENT FINDINGS:

IL-1 is a pivotal cytokine of the innate immune system. Anti-IL-1 agents are currently used for the treatment of several autoimmune and autoinflammatory conditions. Recently, the role of IL-1 has also emerged in cardiovascular diseases. Indeed, two recent randomized controlled trials have shown that the IL-1 receptor antagonist anakinra is effective for the treatment of idiopathic recurrent pericarditis and the IL-1β blocking agent canakinumab is effective in reducing myocardial infarction in people at risk. Interestingly, interfering with IL-1 has proved to be also effective in other cardiovascular manifestations, such as myocarditis, arrhythmias, and heart failure. Blocking the IL-1 pathway is a possible new therapeutic strategy, potentially leading to innovative therapies in many acute and chronic cardiovascular diseases.

• Authors: Giacomo Emmi, Maria Letizia Urban, Massimo Imazio, Marco Gattorno, Silvia Maestroni, Giuseppe Lopalco, Luca Cantarini, Domenico Prisco, Antonio Brucato
• Journal: Current cardiology reports (Curr Cardiol Rep) Vol. 20 Issue 8 Pg. 61 (06 14 2018) ISSN: 1534-3170 [Electronic] United States
• PMID: 29904899 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Interleukin 1 Receptor Antagonist Protein
• Interleukin-1
• canakinumab

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Cardiovascular Diseases (drug therapy)
• Humans
• Interleukin 1 Receptor Antagonist Protein (therapeutic use)
• Interleukin-1 (antagonists & inhibitors)
• Myocardial Infarction (prevention & control)
• Pericarditis (drug therapy)
• Randomized Controlled Trials as Topic